About: Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://www.hindawi.com/isrn/immunology/2012/208903/
Description	Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphomas in Western countries. Implementation of immunotherapy using monoclonal antibodies to therapeutic protocols has led to dramatic improvements in overall survival. DLBCL became a model of a successful immunochemotherapy concept. Despite this fact, there is still a proportion of patients who do not respond to or relapse early after treatment. Growing evidence suggests that host antitumor immunity is suppressed by lymphoma cells in many ways. First, host cytotoxic T cells are directly suppressed by interaction with programmed cell death (PD) ligand on lymphoma cell surface and a similar mechanism enhances the activity of suppressive regulatory T cells (Tregs). Second, tumor cells escape host cytotoxic cells due to lower immunogenicity caused by reduced expression of HLA antigens. Both mechanisms have an origin in primary genetic events in lymphomagenesis. Rearrangement of MHC class II transcriptional activator (CIITA) gene and amplification of Janus kinase (JAK2) gene lead to enhanced expression of PD ligands 1 and 2, higher proliferation activity, and lower expression of HLA. This paper summarizes current knowledge about clinically relevant immune escape mechanisms in DLBCL. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphomas in Western countries. Implementation of immunotherapy using monoclonal antibodies to therapeutic protocols has led to dramatic improvements in overall survival. DLBCL became a model of a successful immunochemotherapy concept. Despite this fact, there is still a proportion of patients who do not respond to or relapse early after treatment. Growing evidence suggests that host antitumor immunity is suppressed by lymphoma cells in many ways. First, host cytotoxic T cells are directly suppressed by interaction with programmed cell death (PD) ligand on lymphoma cell surface and a similar mechanism enhances the activity of suppressive regulatory T cells (Tregs). Second, tumor cells escape host cytotoxic cells due to lower immunogenicity caused by reduced expression of HLA antigens. Both mechanisms have an origin in primary genetic events in lymphomagenesis. Rearrangement of MHC class II transcriptional activator (CIITA) gene and amplification of Janus kinase (JAK2) gene lead to enhanced expression of PD ligands 1 and 2, higher proliferation activity, and lower expression of HLA. This paper summarizes current knowledge about clinically relevant immune escape mechanisms in DLBCL. (en)
Title	Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma (en)
skos:prefLabel	Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma (en)
skos:notation	RIV/61989592:15110/12:33141574!RIV13-MZ0-15110___
http://linked.open...avai/predkladatel	Lékařská fakulta
http://linked.open...avai/riv/aktivita	P S Z
http://linked.open...avai/riv/aktivity	P(NT11103), S, Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika	208903
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	PAPAJÍK, Tomáš INDRÁK, Karel Procházka, Vít Jarošová, Marie Nedomová, Radka Prouzová, Zuzana
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	140544
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/12:33141574
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	clinical testing; diffuse large B-cell lymphoma (DLBCL) (en)
http://linked.open.../riv/klicoveSlovo	clinical testing diffuse large B-cell lymphoma (DLBCL)
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[A448AA90992D]
http://linked.open...i/riv/nazevZdroje	ISRN Immunology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	6 (xsd:int)
http://linked.open...vavai/riv/projekt	The analysis of molecular subtypes of diffuse large B-cell lymphoma by high-resolution arrayCGH for determination of genetic changes of prognostic importance
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	2012
http://linked.open...iv/tvurceVysledku	Indrák, Karel Jarošová, Marie Procházka, Vít Papajík, Tomáš Nedomová, Radka Prouzová, Zuzana
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment
issn	2090-5645
number of pages	6 (xsd:int)
http://bibframe.org/vocab/doi	10.5402/2012/208903
http://localhost/t...ganizacniJednotka	15110
is http://linked.open...avai/riv/vysledek of	Immune Escape Mechanisms in Diffuse Larce B-Cell Lymphoma

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software